Workflow
罕见病药物研发
icon
Search documents
Mirum(MIRM) - 2025 Q1 - Earnings Call Transcript
2025-05-07 21:32
Mirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Company Participants Andrew McKibben - Vice President of Investor Relations and FinanceChris Peetz - President and Chief Executive OfficerPeter Radovich - COO & PresidentEric Bjerkholt - Chief Financial OfficerSelena Zhang - Global capital marketsRyan Mcelroy - Equity Research AssociateRyan Deschner - Vice President - Equity Research Conference Call Participants Gavin Clark-Gartner - AnalystJessica Fye - Managing Director & Equi ...
BioMarin Pharmaceutical(BMRN) - 2025 Q1 - Earnings Call Transcript
2025-05-01 20:30
BioMarin Pharmaceutical (BMRN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good day, everyone, and welcome to the BioMarin Pharmaceutical First Quarter twenty twenty five Conference Call. Just a reminder that this conference is being recorded. I would now like to hand things over to Ms. Tracy McCarty. Please go ahead, ma'am. Speaker1 Thank you, operator. To remind you, this non confidential presentation contains forward looking statements about the business prospects of BioMarin Pharmaceutical I ...
Agios Pharmaceuticals(AGIO) - 2025 Q1 - Earnings Call Transcript
2025-05-01 13:02
Agios Pharmaceuticals (AGIO) Q1 2025 Earnings Call May 01, 2025 08:00 AM ET Company Participants Christopher Taylor - VP - IR & Corporate CommunicationsBrian Goff - CEOSarah Gheuens - Chief Medical Officer and Head of Research & DevelopmentTsveta Milanova - CCOCecilia Jones - CFOHiromichi Nagayumi - Associate - Biotech Equity ResearchAmanda Acosta-Ruiz - Equity Research Associate - Biotechnology Conference Call Participants Gregory Renza - Director & Senior Analyst of Biotechnology Equity ResearchAlec Stran ...
Amicus Therapeutics(FOLD) - 2025 Q1 - Earnings Call Transcript
2025-05-01 12:30
Amicus Therapeutics (FOLD) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the Amicus Therapeutics first quarter twenty twenty five financial results conference call and webcast. At this time, participants are in a listen only mode. Later, we will conduct a question and answer session, and instructions will follow at that time. As a reminder, this conference call, it is being recorded. I would now like to turn the conference call over to your host, ...
Amicus Therapeutics(FOLD) - 2025 Q1 - Earnings Call Transcript
2025-05-01 12:30
Amicus Therapeutics (FOLD) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor RelationsBradley Campbell - CEO, President & DirectorSébastien Martel - Chief Business OfficerJeffrey Castelli - Chief Development OfficerSimon Harford - CFOJoshua Fleishman - Biotech Equity Research Associate Conference Call Participants Anupam Rama - AnalystNone - AnalystDennis Ding - Vice President - Equity Research AnalystRick Miller - AnalystGil Blum - Senior Analyst ...
Mirum(MIRM) - 2024 Q4 - Earnings Call Transcript
2025-02-27 12:10
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Chris Peetz - Chief Executive Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Jessica Fye - JPMorgan David Lebowitz - Citi Rohit Bhasin - Morgan Stanley Ryan Deschner - Raymond James Jonathan Wolleben - Cit ...
舒泰神:会计师关于舒泰神(北京)生物制药股份有限公司向特定对象发行股票的审核问询函的回复(修订稿)(豁免版)
2023-04-20 09:13
舒泰神(北京)生物制药股份有限公司 向特定对象发行股票的审核问询函的回复 天衡专字(2023) 00831 号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台(http://ac.mcf.mor.cn)"进行营" "进行" 舒泰神(北京)生物制药股份有限公司 向特定对象发行股票的审核问询函的回复 天衡专字(2023) 00831 号 深圳证券交易所: 根据贵所于 2023年3月 16 日出具的《关于舒泰神(北京)生物制药股份 有限公司申请向特定对象发行股票的审核间询函》(审核函(2023)020046号) 所列的问题,天衡会计师事务所(特殊普通合伙)(以下简称"本所"或"申报 会计师")作为舒泰神(北京)生物制药股份有限公司(以下简称"舒泰神"、"公 司"、"发行人"或"申请人")向特定对象发行股票的申报会计师,我们对反馈意见 中需申报会计师核查的相关问题进行了认真核查,现将有关情况汇报说明如下: 一、申报材料显示,本次发行拟募集资金总额不超过58,000万元,全部用 于创新药物研发项目,具体包括 BDB-001 注射液、注射用 STSP-0601、 STSA-1002和STSA-1005联合用药三 ...
CANBRIDGE(01228) - 2022 H2 - Earnings Call Transcript
2023-03-31 17:00
CANbridge Pharmaceuticals (01228) H2 2022 Earnings Call March 31, 2023 12:00 PM ET Speaker0 Good morning, everyone. Welcome to Cambridge Pharmaceuticals twenty twenty two twelve Month Annual Results Conference Call. Today, it's a great honor to have Doctor. James Shre, Founder, Chairman and CEO of Cambridge Pharmaceuticals Doctor. Gerald Cox, Chief Medical Officer and Chief Development Strategist Glenn Hassan, Chief Financial Officer and Sophie Hsieh, Director of Investor Relations. Management team will giv ...